drugset / Trial / NCT02766049
Study of Anti-HIV Cellular Therapy Based on Dendritic Cells Pulsed With Chemically Inactivated Virus
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The aim of this study was to assess tolerability and safety of three different formulations of an anti-HIV immunotherapy based on autologous dendritic cells (DCs) pulsed with HIV chemically inactivated with Aldrithiol™-2 (AT-2). Patients were chronically infected with HIV, naïve for antiretroviral drugs. A possible immunological and virological favorable impact was also assessed.
Timeline
- Start
- 2010-02
- Primary completion
- 2014-05
- Completion
- 2014-05
Publications
- Background Lu W, Arraes LC, Ferreira WT, Andrieu JM. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med. 2004 Dec;10(12):1359-65. doi: 10.1038/nm1147. Epub 2004 Nov 28.
- Background Oshiro TM, de Almeida A, da Silva Duarte AJ. Dendritic cell immunotherapy for HIV infection: from theory to reality. Immunotherapy. 2009 Nov;1(6):1039-51. doi: 10.2217/imt.09.68.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC10e6+HIV-AT2 | Cell therapy | 3e+06 cells | — |
| Subject | DC10e6+HIV-AT2 | Cell therapy | 3e+07 cells | — |
| Subject | autologous dendritic cells | Cell therapy | 3e+07 cells | — |